Cencora, Inc. (NYSE:COR) reported Q3 2025 sales of $80.66 billion, up 8.7%, beating expectations. U.S. Healthcare Solutions revenue increased by 8.5%, while International Healthcare Solutions revenue grew by 10.5%. Adjusted earnings were $4.00, up 19.8% year over year.

Cencora’s adjusted gross profit reached $2.9 billion, up 20.7%, with adjusted operating income at $1.1 billion, up 20.6%. The company updated its fiscal year 2025 financial guidance, expecting adjusted earnings of $15.85-$16.00 versus prior guidance of $15.70-$15.95.

The company updated its fiscal 2025 sales guidance to approximately $320.31 billion, with revenue growth projected at 9%. U.S. Healthcare Solutions segment revenue growth is expected between 9%-10%, while International Healthcare Solutions segment revenue growth is projected to be in the range of 6%-7%.

During the earnings call, Cencora discussed the impact of policy changes like Most Favored Nation (MFN) and tariffs. The company remains confident in its supply chain stability and is monitoring brand versus generic supply chains for potential shortages and disruptions.

Read more at Yahoo Finance: Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook